Genprex (NASDAQ:GNPX) Issues Quarterly Earnings Results

Genprex (NASDAQ:GNPX) posted its earnings results on Friday. The company reported ($5.30) EPS for the quarter, FiscalAI reports.

Genprex Price Performance

Shares of GNPX traded down $0.13 during trading hours on Friday, hitting $2.08. 11,447 shares of the stock were exchanged, compared to its average volume of 165,495. Genprex has a fifty-two week low of $1.71 and a fifty-two week high of $98.78. The business has a 50-day moving average of $2.65 and a 200-day moving average of $17.86. The firm has a market capitalization of $1.71 million, a P/E ratio of -0.02 and a beta of -0.95.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Genprex in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

About Genprex

Genprex, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for cancer and other serious diseases. The company’s approach is based on delivering therapeutic genes to diseased cells using non-viral delivery systems, including lipid nanoparticles. Genprex’s lead program, REQORSA Immunogene Therapy, is designed to deliver the TUSC2 tumor-suppressor gene to cancer cells. The company has been evaluating REQORSA in combination with established treatments for non-small cell lung cancer, including targeted and immune-based therapies.